Thalidomide and cancer cachexia: old problem, new hope?
Thalidomide and cancer cachexia: old problem, new hope?
The cancer cachexia syndrome is common. Significant weight loss occurs in approximately 50% of oncology patients, with even higher values in those with gastrointestinal tumours.1 In pancreatic cancer, approximately 80% of patients will become severely malnourished. The development of cachexia is not only distressing for patients and their families, it is also associated with a much worse clinical outcome. Malnourished patients undergoing surgery for cancer have morbidity and mortality rates of three to four times those of their better nourished counterparts,2 and wasted weakened patients also tolerate chemoradiation poorly. Ultimately, malnutrition itself can be considered to be the final cause of death in approximately 30% of cancer patients. It occurs once patients have lost about one third of their premorbid body weight.
thalidomide, cachexia, pancreatic cancer, weight loss, randomised controlled trial
447-448
Stroud, M.A.
1665ae65-0898-4848-bf0d-baec8f2bb078
2005
Stroud, M.A.
1665ae65-0898-4848-bf0d-baec8f2bb078
Stroud, M.A.
(2005)
Thalidomide and cancer cachexia: old problem, new hope?
Gut, 54 (4), .
Abstract
The cancer cachexia syndrome is common. Significant weight loss occurs in approximately 50% of oncology patients, with even higher values in those with gastrointestinal tumours.1 In pancreatic cancer, approximately 80% of patients will become severely malnourished. The development of cachexia is not only distressing for patients and their families, it is also associated with a much worse clinical outcome. Malnourished patients undergoing surgery for cancer have morbidity and mortality rates of three to four times those of their better nourished counterparts,2 and wasted weakened patients also tolerate chemoradiation poorly. Ultimately, malnutrition itself can be considered to be the final cause of death in approximately 30% of cancer patients. It occurs once patients have lost about one third of their premorbid body weight.
This record has no associated files available for download.
More information
Published date: 2005
Keywords:
thalidomide, cachexia, pancreatic cancer, weight loss, randomised controlled trial
Identifiers
Local EPrints ID: 26004
URI: http://eprints.soton.ac.uk/id/eprint/26004
ISSN: 0017-5749
PURE UUID: e40fbf5a-d557-4473-8254-42ea6fa4e612
Catalogue record
Date deposited: 19 Apr 2006
Last modified: 22 Jul 2022 20:32
Export record
Contributors
Author:
M.A. Stroud
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics